NATCO Pharma 43rd AGM Key Proceedings and Capital Raise Approval
Natco Pharma Ltd · Annual General Meeting · 30 Sept 2026, 6:14 pm
NATCO Pharma 43rd AGM Key Proceedings and Capital Raise Approval NATCO Pharma held its 43rd Annual General Meeting on 30th Sep'26, considering key ordinary and special resolutions. The company sought approval to raise funds up to ₹2,000 crore in one or more tranches via preferential issue, rights issue, private placement, QIP, or other permissible modes. Shareholders also considered the adoption of FY25-26 audited financial statements, the confirmation of three interim dividends totaling ₹5.00 per share paid for FY25-26, and the re-appointment of Director P.S.R.K. Prasad. Combined e-voting results will be declared within two working days.
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet · 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 · 14 Nov 2026
- Q2 FY27 Earnings Presentation · 13 Nov 2026
- Un audited Financial Results for the quarter and half year ended 30th September, 2026 · 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Outcome of Board Meeting · 13 Nov 2026
- Intimation of schedule of Concall · 13 Nov 2026
